Patents by Inventor Sami Karaborni

Sami Karaborni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects
    Publication number: 20140350018
    Abstract: Methods of reducing undesirable side effects during therapeutic treatment using monomethyl fumarate and prodrugs of monomethyl fumarate are disclosed.
    Type: Application
    Filed: August 22, 2013
    Publication date: November 27, 2014
    Applicant: XenoPort, Inc.
    Inventors: Kenneth C. Cundy, Sami Karaborni, Peter A. Virsik
  • Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
    Publication number: 20140348915
    Abstract: Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclosed.
    Type: Application
    Filed: August 22, 2013
    Publication date: November 27, 2014
    Applicant: XenoPort, Inc.
    Inventors: Sami Karaborni, Laura Elizabeth Bauer, Chen Mao, Ching Wah Chong, David J. Wustrow, Peter A. Virsik
  • Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
    Publication number: 20140348914
    Abstract: Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclosed.
    Type: Application
    Filed: August 22, 2013
    Publication date: November 27, 2014
    Applicant: XenoPort, Inc.
    Inventors: Sami Karaborni, Sarina Grace Harris Ma, Chen Mao, Ching Wah Chong, Peter Robert Prinz Freed, Mesut Ciper, Stefanie Krenzlin, David J. Wustrow, Peter A. Virsik
  • PHARMACEUTICAL COMPOSITIONS OF DIMETHYL FUMARATE
    Publication number: 20140284245
    Abstract: Pharmaceutical compositions and dosage forms of dimethyl fumarate containing low levels of certain impurities are disclosed.
    Type: Application
    Filed: March 24, 2014
    Publication date: September 25, 2014
    Applicant: XenoPort, Inc.
    Inventors: Sami Karaborni, Wei Chen, Suresh Kumar Manthati
  • Levodopa prodrug mesylate hydrate
    Patent number: 8722733
    Abstract: Crystalline (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate, hydrate, methods of making the hydrate, pharmaceutical compositions containing the hydrate, and methods of using the hydrate to treat diseases or disorders such as Parkinson's disease are provided.
    Type: Grant
    Filed: February 18, 2013
    Date of Patent: May 13, 2014
    Assignee: XenoPort, Inc.
    Inventors: Sami Karaborni, Manshiu Leung, Chen Mao, Venkat R. Thalladi
  • Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
    Publication number: 20140065211
    Abstract: Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclosed.
    Type: Application
    Filed: August 22, 2013
    Publication date: March 6, 2014
    Applicant: XenoPort, Inc.
    Inventors: Sami Karaborni, Sarina Grace Harris Ma, Chen Mao, Ching Wah Chong, Peter Robert Prinz Freed, Mesut Ciper, Stefanie Krenzlin, David J. Wustrow, Peter A. Virsik
  • Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects
    Publication number: 20140057917
    Abstract: Methods of reducing undesirable side effects during therapeutic treatment using monomethyl fumarate and prodrugs of monomethyl fumarate are disclosed.
    Type: Application
    Filed: August 22, 2013
    Publication date: February 27, 2014
    Applicant: XenoPort, Inc.
    Inventors: Kenneth C. Cundy, Sami Karaborni, Peter A. Virsik
  • Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug
    Publication number: 20140056973
    Abstract: Oral dosage forms and granulations with a high loading of a methyl hydrogen fumarate prodrug are disclosed.
    Type: Application
    Filed: August 22, 2013
    Publication date: February 27, 2014
    Applicant: XenoPort, Inc.
    Inventors: Sarina Grace Harris Ma, Laura Elizabeth Bauer, Sami Karaborni, David J. Wustrow, Peter A. Virsik
  • Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
    Publication number: 20140056978
    Abstract: Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclosed.
    Type: Application
    Filed: August 22, 2013
    Publication date: February 27, 2014
    Applicant: XenoPort, Inc.
    Inventors: Sami Karaborni, Laura Elizabeth Bauer, Chen Mao, Ching Wah Chong, David J. Wustrow, Peter A. Virsik
  • Levodopa prodrug mesylate hydrate
    Patent number: 8399513
    Abstract: Crystalline (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate, hydrate, methods of making the hydrate, pharmaceutical compositions containing the hydrate, and methods of using the hydrate to treat diseases or disorders such as Parkinson's disease are provided.
    Type: Grant
    Filed: October 19, 2009
    Date of Patent: March 19, 2013
    Assignee: XenoPort, Inc.
    Inventors: Sami Karaborni, Manshiu Leung, Chen Mao, Venkat Thalladi
  • ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A TRANEXAMIC ACID PRODRUG
    Publication number: 20110184060
    Abstract: Oral dosage forms with a high loading of 4-({[(2-methylpropanoyloxy)ethoxy]carbonylamino}methyl)cyclohexanecarboxylic acid are disclosed.
    Type: Application
    Filed: January 20, 2011
    Publication date: July 28, 2011
    Inventors: Sarina Grace HARRIS MA, Nikhil Pargaonkar, Sami Karaborni
  • SUSTAINED RELEASE ORAL DOSAGE FORMS OF AN R-BACLOFEN PRODRUG
    Publication number: 20100255093
    Abstract: Sustained release oral dosage forms of an R-baclofen prodrug are disclosed.
    Type: Application
    Filed: March 3, 2010
    Publication date: October 7, 2010
    Applicant: XenoPort, Inc.
    Inventors: David E. Edgren, David J. Kidney, Nikhil Pargaonkar, Derrick K. Kim, Gorm Yoder, Sami Karaborni
  • ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A GABAPENTIN PRODRUG
    Publication number: 20100226981
    Abstract: Sustained release oral dosage forms with a high loading of a gabapentin prodrug are disclosed.
    Type: Application
    Filed: March 5, 2010
    Publication date: September 9, 2010
    Applicant: XenoPort, Inc.
    Inventors: Sami Karaborni, Laura E. Maurer, David J. Kidney
  • Levodopa Prodrug Mesylate Hydrate
    Publication number: 20100099761
    Abstract: Crystalline (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate, hydrate, methods of making the hydrate, pharmaceutical compositions containing the hydrate, and methods of using the hydrate to treat diseases or disorders such as Parkinson's disease are provided.
    Type: Application
    Filed: October 19, 2009
    Publication date: April 22, 2010
    Inventors: Sami Karaborni, Manshiu Leung, Chen Mao, Venkat R. Thalladi
  • Mannitol formulation for integrin receptor antagonist
    Publication number: 20060030581
    Abstract: Disclosed are pharmaceutical compositions of an integrin ?v?3 receptor antagonist containing mannitol as the binding agent. The compositions are prepared by wet granulation or direct compression tablet formulation. These pharmaceutical formulations are useful for inhibiting bone resorption associated with osteoporosis, metastatic bone disease, hypercalcemia of malignancy, and Paget's disease.
    Type: Application
    Filed: September 16, 2003
    Publication date: February 9, 2006
    Inventors: Laura DeBusi, Sami Karaborni, Bozen Matuszewska, Adama Procopio, Wei Xu, Chia-Yi Yang
  • Pharmaceutical compositions containing an hiv integrase inhibitor and a nonionic surfactant
    Publication number: 20050165000
    Abstract: Pharmaceutical compositions comprise a therapeutically effective amount of an 8-hydroxy-1,6-naphthyridine-7-carboxamide of Formula (I), or a pharmaceutically acceptable salt thereof: and a nonionic surfactant; wherein R1, R2, R3 and Q1 are defined herein. Compounds of Formula (I) are HIV integrase inhibitors, and the pharmaceutical compositions are useful for preventing or treating HIV infection or for preventing, treating, or delaying the onset of AIDS. The pharmaceutical compositions are typically administered orally, for example, in the form of capsules or tablets, and can provide good oral bioavailability. Methods for preparing encapsulated and tabletted forms of the pharmaceutical compositions are described.
    Type: Application
    Filed: March 13, 2003
    Publication date: July 28, 2005
    Inventors: Sandra Robertson, Maria Cruanes, Sami karaborni, Drazen Ostovic, Xi-Yong Fu, Ashkan Kamali, Santipharp Panmai